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(Correspondence should be addressed to G A Gray; Email: gillian.gray@ed.ac.uk)AbstractOestrogen protects the heart from ischaemic injury. The current
study aims to characterise two novel oestrogen receptor (ER)
ligands, an ERa agonist ERA-45 and an ERb antagonist
ERB-88, and then use them to investigate the roles of ERa and
ERb in mediating the cardioprotection by E from ischaemia–
reperfusion injury in the rat. The ER ligands were characterised
by gene transactivation assay using ER-transfected Chinese
hamster ovary (CHO) cells and in bioavailability studies in vivo.
Female rats (nZ48) were ovariectomised and implanted with
17b-oestradiol (17bE2) releasing or placebo pellets. ERA-45,
ERB-88 or vehicle was administered for 5 days prior to
ischaemia–reperfusion studies. Necrosis, neutrophil infiltration
(myeloperoxidase activity) and oxidant stress production
(electron paramagnetic resonance) from the area-at-risk were
measured to assess reperfusion injury. TheERa agonist ERA-45Journal of Endocrinology (2008) 197, 493–501
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distribution, and reproduction in any medium, provided the original work is propshowed more than 35-fold selectivity for ERa compared with
ERb gene transactivation. In vitro, the ERb antagonist ERB-88
inhibited transactivation by 17bE2 via ERb with 46-fold
selectivity relative to inhibition via ERa. In vivo, 17bE2
significantly reduced neutrophil infiltration, oxidant stress and
necrosis following ischaemia and reperfusion. Cardioprotection
by 17bE2 was not inhibited by ERB-88 but was completely
reproduced by ERA-45. In conclusion, protection of the rat
heart after ischaemia–reperfusion by 17bE2 is achieved through
the reduction of cardiomyocyte death, neutrophil infiltration
and oxygen-free radical availability.The results of this study
indicate that these effects are primarily mediated via activation
of ERa.
Journal of Endocrinology (2008) 197, 493–501Introduction
Premenopausal women have a lower incidence of cardiovas-
cular disease compared with postmenopausal women or age-
matched men (reviewed in Gray et al. 2001, Jeanes et al. 2007).
The production of oestrogen is thought to confer this
protective effect in premenopausal women. Experimentally,
administration of 17b-oestradiol (17bE2) reduces infarct size
(Hale et al. 1996, Patten et al. 2004, Kim et al. 2006) and the
inflammatory response associated with myocardial ischaemia–
reperfusion injury in ovariectomised rats (Squadrito et al.
1997, Jeanes et al. 2007).
There are two known oestrogen receptors (ERs), ERa and
ERb. The receptors are members of the steroid hormone
receptor family with distinct tissue distribution and transcrip-
tional activity (Mendelsohn & Karas 2005). ERa is expressed
in human cardiomyocytes (Mendelsohn & Karas 2005) while
ERb has been identified in cardiomyocytes and fibroblasts
(Taylor et al. 2000). A similar ER distribution has been
reported in the rat heart (Grohe et al. 1997, 1998, Jankowskiet al. 2001, Yang et al. 2004). Experiments using the non-
selective ER antagonist ICI 182 780 have demonstrated that
the 17bE2-induced reduction in infarct size is ER mediated
(Hayashi et al. 1995, Dubey et al. 2001, Booth et al. 2003).
However, the lack of selective ligands has prevented
identification of specific receptors involved. Attempts have
been made to investigate the roles of ERa and ERb using
mice genetically altered to ablate the ERa (ERKO) or ERb
(bERKO). These mouse studies have failed to provide a clear
answer as the protective effects of E in ischaemia reperfusion
are reported to be lost in both ERKO (Zhai et al. 2000a,
Wang et al. 2006) and bERKO mice (Gabel et al. 2005).
Neutrophils invade the myocardium during reperfusion and
are an important source of oxidant stress causing injury
(Reimer et al. 1989). In vivo, the inhibition of myocardial
adhesion molecule expression by oestrogen reduces neutrophil
infiltration into the reperfused myocardium (Delyani et al.
1996). In vitro, oestrogen has been shown to inhibit neutrophil
activation (Squadrito et al. 1997). Isolated neutrophils express
both ERa and ERb (Stygar et al. 2006), but the receptorDOI: 10.1677/JOE-08-0071
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been identified.
The aim of the current study was to investigate the roles of
ERa and ERb in mediating the chronic effects of 17bE2 on
infarct size, neutrophil infiltration and oxidative stress
following ischaemia and reperfusion in ovariectomised rats.
The study used an ERa-selective agonist ERA-45 and a novel
ERb-selective antagonist ERB-88.
This study is the first to use a selective ERb antagonist to
investigate the effects of 17bE2 in vivo. The antagonist did not
inhibit the reduction in infarct size, neutrophil infiltration and
free radical release in hearts from 17bE2-treated rats. However,
these effects of 17bE2 were all reproduced by the selective
ERa agonist. Together, these observations suggest that the
cardioprotective effects of oestrogen in this ratmodel of ischaemia
and reperfusion are mediated via activation of the ERa.Materials and Methods
The investigation conforms with the UK Home Office
guidelines as outlined in the Animals (Scientific Procedures)
Act 1988 and was approved by the University of Edinburgh
Ethical Review Committee.In vitro characterisation of compound activity
An ERa-selective agonist ERA-45 and an ERb antagonist
ERB-88 were used for investigation of the roles of ERa and
ERb. The activity of these compounds was first tested using in
an in vitro gene transactivation assay (De Gooyer et al. 2003).
CHO cells stably transfected with human ERa, the rat oxytocin
promoter (RO) with firefly luciferase reporter gene (LUC)
hERa-RO-LUC or human ERb-RO-LUC was cultured in
medium with 5% charcoal-treated supplemented-defined
bovine calf serum. For the assay, 5!104 cells/well were seeded
into a 96-well plate and incubated with compounds (final
ethanol content: 1% v/v) for 16 h in medium with 5% charcoal-
treated supplemented-defined bovine calf serum at 37 8C in a
humidified atmosphere of air supplemented with 5% CO2. Of
the total 250 ml incubation volume, 200 ml were removed and
50 ml LucLite were added for cell lysis and luciferase
measurement. Luciferase activity was measured in a Topcount
luminescence counter (Canberra Packard, Schwadorf, Austria).
Full agonist curves were constructed for oestradiol and the ER
ligands using cells expressing either ERa or ERb. Oestrogenic
antagonist curves (10K11–10K6 M) for ERB-88 and the non-
selective ER antagonist ICI 164 384 (De Gooyer et al. 2003)
were determined in CHO cells as described above, in the
presence of 0.1!10K9 M or 0.4!10K9 M 17bE2 for ERa and
ERb respectively.Pharmacokinetic studies in vivo
To confirm that appropriate concentrations of compounds
were achieved in vivo, pharmacokinetic studies were carriedJournal of Endocrinology (2008) 197, 493–501out in female rats. The ERa-selective agonist ERA-45
(prepared in 5% (w/v) mannitol 0.5% (w/v) gelatin) was
administered at a dose of 3.4 mg/kg p.o. Compound
concentration in plasma was assessed by LCMS-MS in
samples taken from the jugular vein at hourly intervals after
administration. The ERb antagonist ERB-88 (also prepared
in 5% (w/v) mannitol 0.5% (w/v) gelatin) was administered
s.c. at a dose of 0.68 mg/kg and the samples were
subsequently taken for analysis of plasma concentration as
described above.Experimental design
Two studies were carried out. The first (nZ30) was designed
to investigate the influence of the selective ERa agonist and
ERb antagonist on ischaemia–reperfusion injury in the rat
in vivo, including the area-at-risk (AAR), necrotic area and
also free radical production from the AAR. In placebo-treated
ovariectomised rats, the ERa agonist ERA-45 or vehicle (5%
(w/v) mannitol 0.5% (w/v) gelatin) was administered twice
daily for 5 days prior to the experiment by gavage at a dosage
of 75 mg/kg. The ERb antagonist or vehicle (PBS) was
administered at a dose of 1 mg/kg to ovariectomised rats
treated with 17bE2 or placebo, for 5 days prior to the
experiment by s.c. injection. In both cases, a final dose was
given 2–3 h before the experiment.
The second study (nZ18) aimed to investigate the effects of
the selective ERa agonist on neutrophil infiltration, assessed
by myeloperoxidase (MPO) activity. For these studies, ERA-
45 was administered as mentioned above.
All studies used female Wistar rats (170–200 g; Charles
River, Marlow, UK). Rats were ovariectomised under
isoflurane anaesthesia (4% induction and 2.5% maintenance)
and implanted with pellets (Innovative Research of America,
Sarasota, FL, USA) releasing 17bE2 (2 mg/day for 21 days) or
placebo. Preliminary experiments confirmed that this method
achieved a plasma concentration of oestrogen in the
physiological range (61.42G7.7 pg/ml, nZ6, RIA, Bio-
Stat Diagnostics, Stockport, UK). The rats received 17bE2 or
placebo for a minimum of 14 days prior to experimental use.Ischaemia–reperfusion protocol
Rats were anaesthetised with 60 mg/kg sodium pentabarbi-
tone i.p. (Sagatal, Rhone Merieux, UK). The procedures
were carried out as described previously (Jeanes et al. 2006).
Briefly, the carotid artery and jugular vein were cannulated for
the measurement of mean arterial blood pressure (MABP)
and administration of anaesthetic respectively. The rats were
intubated and ventilated with oxygen-enriched room air
(60 strokes/min; 0.1 ml/g). Body temperature was main-
tained by a thermostatically controlled under blanket. The
chest was then opened at the fourth intercostal space, the
heart was temporarily removed from the chest and the left
coronary artery (LCA) ligated (5/0 Mersilk, Ethicon, UK).
Once the heart was replaced in the chest, it was allowed awww.endocrinology-journals.org
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occluded through the formation of a snare. After 45 min of
ischaemia, the snare was released and a 2-h reperfusion period
followed. At the end of the 2 h of reperfusion, the LCA was
permanently occluded and 1 ml Evans blue dye (1% in saline)
was administered via the jugular vein. The heart was then
removed from the chest and rapidly frozen for determination
of the necrotic area and AAR. For MPO activity, the right
ventricle and atria were removed from separate hearts and the
ischaemic and non-ischaemic areas of the left ventricle
separated prior to rapid freezing. For experiments aimed at
determination of oxidative stress production, the heart was
removed from the chest prior to injection of Evans blue and
set on the Langendorff perfusion set-up. In all experiments,
the uterus was removed and weighed for confirmation of
hormone deficiency or delivery.MPO activity
Neutrophil infiltration into the ischaemic myocardium was
assessed through measurement of MPO activity, as previously
described (Jeanes et al. 2006). Briefly, the ischaemic area was
homogenised in buffer containing 20 mM sodium phosphate
(pH 4.7) 1.5!10K2 M EDTA and 10K1 M sodium chloride
and then centrifuged at 10 000 g at 4 8C for 15 min. The
resulting pellet was resuspended and homogenised in sodium
phosphate buffer (pH 5.4) containing 0.5% hexadecyltri-
methylammonium bromide. Homogenisation was followed by
four cycles of freeze-thaw, a brief sonication and 15-min
centrifugation at 10 000 g at 4 8C. The resulting supernatant
(30 ml) was mixed with 200 ml citrate phosphate buffer
containing o-dianisidine dihydrochloride and 0.0015% hydro-
gen peroxide. The absorbance was measured over 10 min at
405 nm. MPO activity was defined as the quantity of enzyme
degrading 1 mmol peroxide per min at 25 8C, expressed in
units per gram of weight.Electron paramagnetic resonance (EPR)
EPR was used to measure the free radical production from
hearts that had undergone ischaemia–reperfusion in vivo.
Hearts were removed after 2 h of reperfusion and rapidly
perfused in retrograde mode with warmed and gassed Krebs–
Henseleit solution, as described below. After a short
stabilisation period, the reversible snare was re-tied and
10 ml 10K1 M CP-H (1-hydroxy-3-carboxy-pyrolidine;
Axxora Ltd, Nottingham, UK) spin trap was injected into
the perfusate above the heart via an injection arm. A 500 ml
aliquot of the resulting perfusate was collected from the base
of the heart (drops 6–11 after the injection of spin trap). This
was repeated four times to obtain an average measurement for
each heart. The snare around the LCA was then released to
allow perfusion of the entire myocardium and the procedure
of perfusion and administration of CP-H spin trap was
repeated. Finally, to determine the contribution of superoxide
radicals to the oxidant signal generated by the heart 500 Uwww.endocrinology-journals.orgsuperoxide dismutase (SOD) was perfused through the entire
heart along with the CP-H spin trap. The collected samples
were incubated at 37 8C for 20 min and then the
concentration of the free radical was measured using the
EPR magnet (Magnettech MiniScope MS200 and Mini-
Scope Control 6.51 software, Magnettech, Berlin, Germany),
with the settings below: B0 field: 3357 G; Sweep: 44 G;
Sweep time: 30 s; No. of Passes: 1; Modulation Amplitude:
1500 mG; Microwave Power: 20 mW). The results are
expressed as an estimate of the signal generated from the
ischaemic myocardium, calculated by subtracting the signal
obtained from the non-ischaemic myocardium from the
signal obtained from the entire heart.Measurement of infarct size
The extent of myocardial damage was assessed using the
triphenyltetrazolium chloride–Evans blue technique, as
described previously (Jeanes et al. 2006). The heart was cut
into 2–3 mm slices from apex to base and then incubated in
2,3,5-triphenyltetrazolium chloride (1% (w/v) in saline) at
37 8C for 15 min. The heart was then fixed in 10% formalin
for 10 min and rinsed in 0.9% saline. Three distinct areas of
the heart result, the Evans blue-stained non-ischaemic
myocardium, the red ischaemic non-necrotic tissue and the
white necrotic tissue were separated, blotted dry and weighed.
The AAR was taken as the red ischaemic non-necrotic tissue
and the white necrotic tissue; this was expressed as a
percentage of the total heart weight. The necrotic tissue
was expressed as a percentage of the AAR.Statistical analysis
Statistical analysis was performed using PRISM (GraphPad,
San Diego, CA, USA). Two- and one-way ANOVAs with
Bonferroni post hoc or paired and unpaired two-tailed Student’s
t-tests were used where appropriate. Statistical difference was
taken as P!0.05.Chemicals
ERa agonist ERA-45 and ERb antagonist ERB-88 were
supplied by Organon. All other chemicals were from Sigma–
Aldrich unless stated otherwise.Results
Characterisation of compounds: in vitro transactivation assay
The ERa agonist ERA-45 activated luciferase expression in
CHO cells transfected with recombinant human ERa with
an EC50 of 3.7!10
K10 M (95% confidence limits 3.2 and
4.4!10K10 M, nZ4; Fig. 1a). The EC50 for activation of
human ERb in the same cell system was 1.3!10K8 M (95%
confidence limits 0.9 and 17.7!10K8 M, nZ4; Fig. 1b).Journal of Endocrinology (2008) 197, 493–501
Figure 1 Characterisation of ER ligands in an in vitro gene transactivation assay. Activation by 17bE2, the ERa
agonist ERA-45 and the ERb antagonist ERB-88 of (a) human ERa and (b) human ERb. Antagonist activity of
the ERa/ERb antagonist ICI 164 384 and the ERb antagonist ERB-88 at (c) human ERa and (d) human ERb
stimulated with 0.1 or 0.4 nM 17bE2 respectively; nZ5–7 per curve.
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K11 M (95%
confidence limits 1.7 and 4.1!10K11 M; Fig. 1a) and ERb
with an EC50 of 6.5!10
K11 M (95% confidence limits 4.9
and 8.7!10K11 M; Fig. 1b).
The non-selective ER antagonist ICI 164 384 inhibited
activation by 17bE2 in cells expressing both ERa (EC50 of 5.7!
10K9 M, 95% confidence limits 4.1 and 7.7!10K9 M; Fig. 1c)
andERb (EC50 of 2.6!10
K8 M, 95%confidence limits 1.8 and
3.6!10K8 M; Fig. 1d). By contrast, ERB-88-inhibited gene
transactivation inducedby17bE2 in cells expressing recombinant
human ERb with an IC50 of 2.1!10
K9 M (95% confidence
limits 0.8 and 5.7!10K9 M; Fig. 1d) and did not inhibit
ERa-mediated gene activation up to 10K6 M (Fig. 1c). The
ERa agonist ERA-45, at concentration up to 10K5 M, did not
inhibit activation of either receptor by 17bE2 (data not shown).Characterisation of compounds: in vivo bioavailability
Plasma concentration rose to a peak of 63 nM at 30 min after
dosing of female rats with ERA-45 (3.4 mg/kg p.o.) and
dropped to a minimum of 3.6 nM at 12 h after dosing, the
half-life of ERA-45 was 5.5G0.78 h (nZ3). The target
plasma concentration to achieve selective activation of ERaJournal of Endocrinology (2008) 197, 493–501was 1 nM, based on in vitro studies. A dose of 0.75 mg/kg
p.o. was selected for the in vivo ischaemia–reperfusion study,
this was administered twice daily to ensure that plasma levels
were maintained at a suitable level for activation of ERa.
Subcutaneous administration of ERB-88 at a dose of
0.68 mg/kg achieved a peak plasma concentration of 241!
10K9 M at 2 h, after administration, this fell to 41!10K9 M at
7 h and to below 10!10K9 M by 24 h (nZ2). The target
plasma concentration to achieve maximal selective blockade of
ERbwas 10K8 M. An s.c. dose of 1 mg/kg was selected for the
in vivo ischaemia–reperfusion study. The final dose of ERB-88
was administered 2–3 h before the experiment began.Body weight and uterine weights
The body weights of all the animals were recorded at the time
of ovariectomy and of ischaemia–reperfusion. There was no
significant difference in body weight at the time of
ovariectomy. At the time of ischaemia–reperfusion, rats that
received 17bE2 or the ERa agonist ERA-45 weighed
significantly less than placebo/vehicle-treated rats (Table 1).
Treatment with ERb antagonist ERB-88 did not have any
influence on weight when given to rats receiving placebo orwww.endocrinology-journals.org
Table 1 The influence of 17b-oestradiol (17bE2) and selective oestrogen receptor (ER) drugs on the body weight, uterine weight and the area-
at-risk after ischaemia reperfusion in the rat. Data shown are meanGS.E.M.
Body weight (BW, g) Uterine weight/BW (%) Area-at-risk (% total heart)
Hormone treatment
PlaceboCvehicle 278G6 0.04G0.01 57G4
17bE2Cvehicle 221G7* 0.25G0.03* 54G2
17bE2CERb antagonist 217G4* 0.23G0.02* 59G2
PlaceboCERa agonist 233G5* 0.12G0.03*,† 55G2
PlaceboCERb antagonist 279G9 0.05G0.01 56G3
A one-way ANOVA with a Bonferroni post hoc test, *P!0.001 compared with placebo; †P!0.001 compared with 17bE2Cvehicle;nZ6–8. BW, body weight.
Oestrogen receptors and cardioprotection . H L JEANES and others 49717bE2 (Table 1). The uterine weights of all animals were
recorded at the experimental end point to confirm the
effective removal of the ovaries and successful hormone
delivery in appropriate animals. Animals receiving placebo/
vehicle had a significantly reduced uterine weight compared
with those receiving either 17bE2 or placebo in combination
with selective ERa agonist (Table 1). The selective ERa
agonist appeared to induce less proliferation than 17bE2
(Table 1). The ERb antagonist ERB-88 had no significant
effect on the uterine weight when given to rats receiving
placebo or 17bE2 (Table 1). These data confirm successful
activation of the ERa by ERA-45 at the dose chosen and a
lack of effect of the chosen dose of ERb antagonist on ERa-
mediated uterine proliferation.Figure 2 Myocardial necrotic tissue after in vivo ischaemia–
reperfusion. Necrotic zone is expressed as a percentage of the
total area-at-risk (AAR). Hormone treatment was placebo with
vehicle, 17bE2 with vehicle, 17bE2 with ERb antagonist ERB-88 or
placebo with ERa agonist ERA-45. Data shown are meansGS.E.M.;
analysed using a two-way ANOVA and a Bonferroni post hoc test;
**P!0.01, *P!0.05 compared with placebo; nZ6–8.In vivo ischaemia–reperfusion
The MABP in the placebo/vehicle-treated group before
ischaemia was 73G13 mmHg (nZ5). This dropped by
w41% at the onset of ischaemia and then recovered during
the initial 15 min of ischaemia to a pre-ischaemic level that
was maintained until the end of the experiment. Treatment
with 17bE2 or selective ER ligands did not have a
significant effect on this pattern or on the MABP at the
end of the ischaemia or reperfusion periods (data not
shown). The heart rate did not change significantly
throughout the protocol in any of the treatment groups
(data not shown).
The total AAR in the placebo/vehicle-treated group was
57.1G3.8% of the total heart. The AAR in the other
treatment groups did not differ significantly from this
(Table 1). 17bE2 significantly (P!0.05) reduced the size of
the necrotic zone within the AAR compared with placebo/
vehicle-treated ovariectomised rats (Fig. 2). Treatment with
the ERb antagonist ERB-88 did not significantly alter this
17bE2-induced decrease in necrotic tissue (Fig. 2). By
contrast, placebo-treated rats receiving the ERa agonist
ERA-45 also displayed a significant reduction in necrotic
tissue compared with placebo/vehicle-treated rats (P!0.01;
Fig. 2). Treatment with ERB-88 after placebo treatment had
no significant effect on infarct size compared with vehicle
(43G3% AAR versus 42G3% AAR, nZ6).www.endocrinology-journals.orgNeutrophil infiltration in vivo
Tissue MPO activity was measured as a marker of neutrophil
infiltration following reperfusion. Supplementation with
17bE2 after ovariectomy significantly (P!0.05) reduced the
amount of MPO activity detected in the AAR compared
with that in hearts from placebo/vehicle-treated rats (Fig. 3).
To determine whether the reduction in infarct size associated
with ERa agonist was linked to a reduction in neutrophil
infiltration, MPO activity was also assessed in this group.
Dosing placebo-treated rats with the selective ERa agonist
also significantly (P!0.05) reduced the level of MPO activity
within the AAR, reproducing the effect of 17bE2 (Fig. 3).Free radical production after in vivo ischaemia–reperfusion
Neutrophils are a major source of oxidant stress following
reperfusion. Any change in neutrophil infiltration should
therefore be correlatedwith a reduction in free radical production
from the AAR. EPR was used to detect the influence of 17bE2
treatment on free radical production by the reperfused AAR of
the myocardium following the in vivo ischaemia–reperfusion
protocol. In hearts from placebo/vehicle-treated animals,Journal of Endocrinology (2008) 197, 493–501
Figure 3 Myeloperoxidase activity in the area-at-risk (AAR) after
ischaemia–reperfusion in vivo and the influence of 17bE2 or ERa
agonist ERA-45 treatment. The hormone treatment prior to
ischaemia–reperfusion was placebo with vehicle, 17bE2 with
vehicle or placebo with ERa agonist ERA-45. Data are expressed as
UgK1 tissue. Data shown are meanGS.E.M.; analysed with a one-
way ANOVA and a Bonferroni post hoc test; *P!0.05 compared
with placebo; nZ5–6.
H L JEANES and others . Oestrogen receptors and cardioprotection498significantly more free radicals were detected in the perfusate
collected from the whole heart than from the non-ischaemic
myocardium alone (3524G834 vs 1055G395 arbitrary units,
PZ0.005, nZ5), demonstrating production from the AAR.
The majority of the oxidant stress could be accounted for by
superoxide radicals as administration of SOD along with the spin
trap significantly decreased free radical production from the
reperfused heart by 53G10.3% (PZ0.04, nZ7).
Significantly fewer free radicalswere generated fromthe AAR
of hearts from animals that received 17bE2 than those that
received placebo/vehicle following ovariectomy (P!0.01;
Fig. 4). This influence of 17bE2 was not modified in heartsFigure 4 The effect of hormone treatment on oxidant stress
generated from the reperfused myocardium. Data shown are the
difference between free radicals produced from the entire heart and
the ligated heart. Hormone treatment was placebo with vehicle,
17bE2 with vehicle, placebo with ERb antagonist ERB-88, 17bE2
with ERb antagonist ERB-88 or placebo with ERa agonist ERA-45.
All data are meanGS.E.M.; analysed using a one-way ANOVA with a
Bonferroni post hoc test; ***P!0.01 compared with placebo;
nZ5–8.
Journal of Endocrinology (2008) 197, 493–501from ERb receptor antagonist-treated rats (P!0.01; Fig. 4).
However, rats that received placebo pellets and the ERa agonist
ERA-45 also had significantly decreased free radical production
compared with the rats treated with placebo/vehicle (P!0.01;
Fig. 4).Discussion
The aim of this study was to identify the roles of ERa and ERb
in mediating the cardioprotection provided by chronic
administration of 17bE2 in a model of ischaemia–reperfusion.
This was achieved using two novel ER ligands that we show,
using a gene transactivation assay, to be a selective agonist at
ERa (ERA-45) and a selective antagonist at ERb (ERB-88).
The results from the current study suggest that ERa is the
predominant ER involved in cardioprotection by 17bE2.
Chronic administration of ERB-88 to ovariectomised rats
receiving 17bE2 had no significant influence on infarct size or
oxidant stress production. In comparison, the cardioprotective
effects of 17bE2 were completely reproduced by ERA-45.
It is well established that 17bE2 provides protection in
experimental models of ischaemia–reperfusion (Stumpf et al.
1977, Squadrito et al. 1997, Zhai et al. 2000b). This protection
is mediated through reduction of ischaemia-induced cell
death (Patten et al. 2004, Patten & Karas 2006), inhibition of
neutrophil infiltration (Squadrito et al. 1997, Jeanes et al.
2006) and reduction of oxidative damage to the myocardium
(Kim et al. 1998, 2006, Mchugh et al. 1998, Urata et al. 2006).
In the present study, we confirmed that both infarct size and
neutrophil infiltration, assessed by myocardial MPO activity,
were reduced in 17bE2-treated animals.
Oxidant stress is an important cause of injury following tissue
reperfusion. Therefore, in the present study, we additionally
aimed to measure free radical release from the reperfused
myocardium using EPR. This technique has previously been
used to detect the brief oxidative burst that occurs following
ischaemia–reperfusion in vitro in isolated buffer-perfused hearts
(Zweier et al. 1989). However, this is the first time that it has
been used to assess free radical production from hearts that have
undergone in vivo ischaemia–reperfusion. In vitro perfusion of
these hearts with the CP-H spin trap was successful in detecting
free radical release. Free radical detection was significantly
reduced when perfusion through the AAR was prevented,
identifying the AAR as the major site of free radical production
in these hearts. The most likely source of oxidative stress within
the AAR is neutrophils that have infiltrated during reperfusion
(McCord 1985). In the present study, the reduction in EPR
signal after dual perfusion of spin trap and SOD demonstrates
that the majorityoffree radicals produced in the myocardiumare
superoxide anions, the predominant free radical released from
neutrophils (Tauber & Babior 1977). Treatment with 17bE2
clearly reduced the oxidant signal generated in the myocardium
after ischaemia reperfusion compared with placebo/vehicle-
treated rats. This reduction corresponds to the reduction in
neutrophil infiltration in 17bE2-treated animals. In thewww.endocrinology-journals.org
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oxidant stress through the electron transfer chain (Lesnefsky et al.
2001) and may also contribute here. 17bE2 has previously been
shown to reduce the oxidative stress from isolated rat
mitochondria (Stirone et al. 2005) and this may be an
additional protective mechanism of 17bE2 in the current
model. Free radical scavenging is also likely to be enhanced
following chronic treatment with 17bE2, as it is known to
upregulate endogenous antioxidant systems, such as glutathione
peroxidase and SOD (Kim et al. 1998, Borras et al. 2005, Urata
et al. 2006).
The principal aim of this study was to identify the roles of
ERa and ERb in mediating the cardioprotective effects of
oestrogen using a selective ERa agonist and a novel ERb
antagonist. In vitro gene transactivation studies showed that
the ERa agonist ERA-45 has w35-fold greater potency for
gene transactivation via ERa, compared with ERb. The dose
of ERA-45 selected for the current study was based on these
in vitro data and extrapolation from parallel in vivo bioavail-
ability studies. The chosen dose was expected to achieve a
plasma concentration of around 1 nM. At this concentration,
we would expect 70–80% activation of the ERa but minimal,
if any, activation of ERb. In rats, ERa is responsible for the
stimulation of epithelial cell proliferation in the uterus that
results in the observed increase in uterine weight when
treated with 17bE2 or ERa agonist (Frasor et al. 2003). ERa
also mediates the 17bE2-induced attenuation of food intake
and weight gain (Roesch 2006). In the present study,
administration of the ERa agonist ERA-45 increased uterine
weight and decreased body weight, consistent with successful
activation of this receptor. The increase in uterine prolifer-
ation with ERA-45 was less than that achieved with 17bE2
suggesting that the selected dose was achieving a less than
maximal effect, as expected from the pharmacokinetic data.
The ERb antagonist ERB-88 also showed clear efficacy and
selectivity in gene transactivation studies. In ERa-transfected
cells activation by 17bE2 was inhibited by the established
ERa/b antagonist ICI 164 384 (Zwart et al. 2007), but ERB-
88 had no influence until 10K6 M. By contrast, at ERb,
activation by 17bE2 was inhibited by both ICI 164 384 and
ERB-88. Based on bioavailability data, the dose used in the
present study should be sufficient to block 80–90% of ERb,
without influencing ERa. While there is no easily
quantifiable measure of ERb activation in vivo to confirm
blockade of this receptor, the lack of influence on uterine or
body weight confirms a lack of effect on ERa.
The ERb antagonist ERB-88 did not attenuate the effects
of 17bE2 on infarct size, or free radical production. ERb has
been detected in the rat heart (Grohe et al. 1998, Jankowski
et al. 2001, Yang et al. 2004) and it was implicated in
mediating cardioprotection following trauma–haemorrhage
in experiments using an ERb agonist (Yu et al. 2006).
However, it does not appear to have a role in mediating
cardioprotection by 17bE2 following ischaemia–reperfusion
in the rat. The results of the present study suggest that 17bE2
is more likely to act through stimulation of ERa in the ratwww.endocrinology-journals.orgheart. This conclusion is supported by the fact that the ERa
agonist ERA-45 completely reproduced the cardioprotective
effects of 17bE2 and the effects of 17bE2 on neutrophil
infiltration and oxidant stress production. In another study,
acute administration of the selective ERa agonist PPT (4,4,4-
4 propyl-(1H)-pyrazole 1,3,5-triyltrisphenol-PPT) 30 min
before ischaemia and reperfusion also reduced infarct size in
the rabbit, while the ERb agonist DPN (2,3-bis(4-hydroxy-
phenyl propionitrile-DPN) failed to provide any cardiopro-
tection (Booth et al. 2005). In this study, cardioprotection via
stimulation of ERa was linked to reduction of C-reactive
protein (CRP) deposition within the infarct area. We have
recently shown that CRP can enhance infarct damage
following permanent ligation of the coronary artery in the
rat (Pepys et al. 2006). Reduction of CRP deposition may also
be a feature of protection following chronic stimulation of
ERa in the present study. However, additional mechanisms
will also contribute, for example, enhanced expression of
endothelial nitric oxide synthase and reduced expression of
adhesion molecules, effects of E that reduce neutrophil
infiltration (Delyani et al. 1996, Squadrito et al. 1997), and
have previously been linked to activation of ERa (Tan et al.
1999, Schrepfer et al. 2006). Rapid activation of Akt, resulting
in a reduction in cardiomyocyte apoptosis following
ischaemia has also been linked to ERa in vitro (Patten et al.
2004, Patten & Karas 2006). Further studies are required to
confirm the cellular mechanisms involved in reduction of
infarct size, neutrophil infiltration and free radical release
following stimulation of ERa in myocardial ischaemia–
reperfusion injury in vivo. In a more recent study, activation of
the ERb, using the ERb agonist DPN, has been shown to
preserve cardiac contractility following ischaemia and
reperfusion in the mouse (Nikolic et al. 2007), although
neither infarct size nor inflammatory cell infiltration was
assessed as end points, making direct comparison with the
present study difficult. Species differences may explain the
apparent variability in contribution of ERa and ERb to
cardioprotection in the rabbit (Booth et al. 2005), rat (present
study) and mouse (Nikolic et al. 2007). It is also possible that
the ERb has a specific role in the preservation of contractile
function that was not identified in the present study.
Alternatively, selective activation of either receptor may not
reflect the actual contributions of the receptors to the effects
of 17bE2 that can activate both receptors. In this sense, the
antagonist data generated in the current study are important
in demonstrating that removal of the ERb does not prevent
reduction of infarct size and oxidant stress generation by
17bE2. Studies using an ERa antagonist would provide
further evidence for a role of ERa, and also reveal whether
ERb can have a role when it is activated by 17bE2 in the
absence of the ERa.
In conclusion, the current study is the first study to
demonstrate, using a combination of ERa agonist and ERb
antagonist, that the cardioprotective properties of 17bE2 in a
rat model of ischaemia–reperfusion are primarily mediated via
stimulation of the ERa.Journal of Endocrinology (2008) 197, 493–501
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